AR096332A1 - Compuestos heterocíclicos tricíclicos condensados como inhibidores de la integrasa del vih - Google Patents
Compuestos heterocíclicos tricíclicos condensados como inhibidores de la integrasa del vihInfo
- Publication number
- AR096332A1 AR096332A1 ARP140101973A ARP140101973A AR096332A1 AR 096332 A1 AR096332 A1 AR 096332A1 AR P140101973 A ARP140101973 A AR P140101973A AR P140101973 A ARP140101973 A AR P140101973A AR 096332 A1 AR096332 A1 AR 096332A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- membered monocyclic
- cycloalkyl
- group
- halo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/16—Peri-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Composiciones que comprenden al menos un derivado heterociclo tricíclico condensado y a procedimientos de uso de derivados heterociclos tricíclicos condensados para el tratamiento o prevención de la infección por el VIH en un sujeto. Reivindicación 1: Un compuesto que tiene la formula (1) y sales farmacéuticamente aceptables de las mismas, en la que: A es alquileno C₁₋₄, alquenileno C₂₋₄, arileno, cicloalquilo C₃₋₇, heteroarilo monocíclico de 5 ó 6 miembros, heterocicloalquilo de 4 a 7 miembros, -O-, -NH-C(O)-, -C(O)NH- o -C(O)-; X es O, -N(alquilo C₁₋₆)- o -C(R¹⁰)(R¹¹), de forma que cuando X = O ó -N(alquilo C₁₋₆)-, R⁴, R⁵, R⁶ y R⁷ son cada uno distinto a -OR⁹, -N(R⁹)₂ o halo; cada aparición de m es de forma independiente de 0 ó 1; n es 0 ó 1, de forma que cuando n es 0, R⁴ y R⁵ no están presentes; R¹ es alquilo C₁₋₆, que está opcionalmente sustituido por hasta 3 grupos seleccionados cada uno de forma independiente de cicloalquilo C₃₋₇, heteroarilo monocíclico de 5 ó 6 miembros, heterocicloalquilo monocíclico de 4 a 6 miembros, arilo C₆₋₁₀, halo, haloalquilo C₁₋₆, -OR⁹, -N(R⁹)₂, -C(O)R⁹, -C(O)N(R⁹)₂, -NHC(O)R⁹ y -SR⁹, en el que dicho grupo cicloalquilo C₃₋₇, dicho grupo heteroarilo monocíclico de 5 ó 6 miembros, dicho grupo heterocicloalquilo monocíclico de 4 a 6-miembros y dicho grupo arilo C₆₋₁₀ pueden estar cada uno opcional e independientemente sustituidos por uno o más grupos seleccionados cada uno de forma independiente de alquilo C₁₋₆, cicloalquilo C₃₋₇ o heteroarilo monocíclico de 5 ó 6 miembros, heterocicloalquilo monocíclico de 4 a 6 miembros, arilo C₆₋₁₀, halo, haloalquilo C₁₋₆, -OR⁹, -N(R⁹)₂, -C(O)R⁹, -C(O)N(R⁹)₂, -NHC(O)R⁹ y -SR⁹; R², R⁵, R⁶, R⁷, R¹⁰ y R¹¹ se seleccionan cada uno de forma independiente de H, alquilo C₁₋₆, cicloalquilo C₃₋₇, halo, haloalquilo C₁₋₆, -OR⁹, -N(R⁹)₂, -C(O)R⁹, -C(O)N(R⁹)₂ y -NHC(O)R⁹, en los que dicho grupo alquilo C₁₋₆ puede estar opcionalmente sustituido por uno o más grupos seleccionados cada uno de forma independiente de halo, -OH, -O(alquilo C₁₋₆), -NH₂, -NH(alquilo C₁₋₆), -N(alquilo C₁₋₆)₂, -SH o -S(alquilo C₁₋₆); R³ es H, alquilo C₁₋₆, cicloalquilo C₃₋₇, haloalquilo C₁₋₆, -C(O)R⁹, -C(O)N(R⁹)₂ y -NHC(O)R⁹, en los que dicho grupo alquilo C₁₋₆ puede estar opcionalmente sustituido por uno o más grupos seleccionados cada uno de forma independiente de halo, -OH, -O(alquilo C₁₋₆), -NH₂, -NH(alquilo C₁₋₆), -N(alquilo C₁₋₆)₂, -SH o -S(alquilo C₁₋₆); R⁴ es H, o R⁴ y R⁵ y el átomo de carbono común al que están unidos se unen para formar un grupo -C(O)- endocíclico; R⁸ se selecciona de alquilo C₁₋₆, -(alquileno C₁₋₃)ₘ-(cicloalquilo C₃₋₇), -(alquileno C₁₋₃)ₘ-(heteroarilo monocíclico de 5 ó 6-miembros), -(alquileno C₁₋₃)ₘ-(heterocicloalquilo monocíclico de 4 a 6 miembros) y -(alquileno C₁₋₃)ₘ-(arilo C₆₋₁₀), en el que dicho grupo cicloalquilo C₃₋₇, dicho grupo heteroarilo monocíclico de 5 ó 6 miembros, dicho grupo heterocicloalquilo monocíclico de 4 a 6 miembros y dicho grupo arilo C₆₋₁₀ pueden estar cada uno opcional e independientemente sustituidos con hasta 5 grupos, seleccionados cada uno de forma independiente de alquilo C₁₋₆, cicloalquilo C₃₋₇, heteroarilo monocíclico de 5 ó 6 miembros, heterocicloalquilo monocíclico de 4 a 6 miembros, arilo C₆₋₁₀, halo, haloalquilo C₁₋₆, -OR⁹, -N(R⁹)₂, -C(O)R⁹, -C(O)N(R⁹)₂, -NHC(O)R⁹ y -SR⁹; y cada aparición de R⁹ se selecciona de forma independiente de H, alquilo C₁₋₆, cicloalquilo C₃₋₇, arilo C₆₋₁₀ y bencilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361824739P | 2013-05-17 | 2013-05-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR096332A1 true AR096332A1 (es) | 2015-12-23 |
Family
ID=51897679
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140101973A AR096332A1 (es) | 2013-05-17 | 2014-05-16 | Compuestos heterocíclicos tricíclicos condensados como inhibidores de la integrasa del vih |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9643982B2 (es) |
| EP (2) | EP3330272B1 (es) |
| AR (1) | AR096332A1 (es) |
| AU (1) | AU2014267951A1 (es) |
| CY (1) | CY1119842T1 (es) |
| DK (1) | DK2997033T3 (es) |
| ES (1) | ES2656696T3 (es) |
| HK (1) | HK1248685A1 (es) |
| HR (1) | HRP20180081T1 (es) |
| HU (1) | HUE036384T2 (es) |
| LT (1) | LT2997033T (es) |
| ME (1) | ME02977B (es) |
| NO (1) | NO3058793T3 (es) |
| PL (1) | PL2997033T3 (es) |
| PT (1) | PT2997033T (es) |
| RS (1) | RS56701B1 (es) |
| SI (1) | SI2997033T1 (es) |
| TW (1) | TWI656122B (es) |
| WO (1) | WO2014183532A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2016027879A1 (ja) | 2014-08-22 | 2017-06-01 | 塩野義製薬株式会社 | インテグラーゼ阻害活性を有する多環性ピリドン誘導体 |
| TWI520963B (zh) * | 2014-12-24 | 2016-02-11 | 國立清華大學 | １，９－二氮萉衍生物及其製法 |
| WO2017113288A1 (en) * | 2015-12-31 | 2017-07-06 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
| JOP20190130A1 (ar) * | 2016-12-02 | 2019-06-02 | Merck Sharp & Dohme | مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv) |
| CN110062627A (zh) * | 2016-12-02 | 2019-07-26 | 默沙东公司 | 可用作hiv整合酶抑制剂的三环杂环化合物 |
| CA3101180A1 (en) * | 2018-04-27 | 2019-10-31 | Merck Sharp & Dohme Corp. | Tricyclic heterocycle compounds useful as hiv integrase inhibitors |
| MX2020012185A (es) | 2018-05-31 | 2021-01-29 | Shionogi & Co | Derivado policiclico de piridona. |
| WO2019230858A1 (ja) | 2018-05-31 | 2019-12-05 | 塩野義製薬株式会社 | 多環性カルバモイルピリドン誘導体 |
| EP3801543A4 (en) | 2018-06-05 | 2022-03-02 | Merck Sharp & Dohme Corp. | HETEROCYCLIC TRICYCLIC COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS |
| WO2019245974A1 (en) | 2018-06-21 | 2019-12-26 | Genentech, Inc. | Solid forms of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use |
| PL3938047T3 (pl) | 2019-03-22 | 2022-11-07 | Gilead Sciences, Inc. | Zmostkowane tricykliczne związki karbamoilopirydonowe i ich zastosowanie farmaceutyczne |
| US20200398978A1 (en) | 2019-06-20 | 2020-12-24 | Bell Helicopter Textron Inc. | Low-drag rotor blade extension |
| WO2021107066A1 (ja) | 2019-11-28 | 2021-06-03 | 塩野義製薬株式会社 | インテグラーゼ阻害剤及び抗ｈｉｖ薬を組み合わせることを特徴とするｈｉｖ感染症の予防及び治療用医薬 |
| AU2021225809B2 (en) * | 2020-02-24 | 2023-08-24 | Gilead Sciences, Inc. | Tetracyclic compounds for treating HIV infection |
| FI4196479T3 (fi) | 2021-01-19 | 2024-01-17 | Gilead Sciences Inc | Substituoituja pyridotriatsiiniyhdisteitä ja niiden käyttöjä |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE550320T1 (de) | 2001-08-10 | 2012-04-15 | Shionogi & Co | Antivirales mittel |
| ES2258668T3 (es) | 2001-10-26 | 2006-09-01 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Hidroxipirimidina carboxamidas n-sustituidas inhibidoras de hiv integrasa. |
| PT1441734E (pt) | 2001-10-26 | 2007-05-31 | Isti Di Ric Di Bio Moleco P An | Di-hidroxipirimidinocarboxamidas inibidoras da integrase do vih |
| ATE370948T1 (de) | 2002-01-17 | 2007-09-15 | Merck & Co Inc | Hydroxynaphthyridinoncarbonsäureamide, die sich als inhibitoren der hiv-integrase eignen |
| EP1578748B1 (en) | 2002-12-27 | 2010-09-15 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Tetrahydro-4h-pyrido[1,2-a]pyrimidines and related compounds useful as hiv integrase inhibitors |
| US7135467B2 (en) | 2003-01-13 | 2006-11-14 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US7037908B2 (en) | 2003-04-24 | 2006-05-02 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| AR046938A1 (es) | 2003-12-12 | 2006-01-04 | Merck & Co Inc | Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares |
| TW200526635A (en) | 2003-12-22 | 2005-08-16 | Shionogi & Co | Hydroxypyrimidinone derivative having HIV integrase inhibitory activity |
| CN1930161A (zh) * | 2004-03-09 | 2007-03-14 | P·安杰莱蒂分子生物学研究所 | Hiv整合酶抑制剂 |
| KR20070026414A (ko) | 2004-03-09 | 2007-03-08 | 머크 앤드 캄파니 인코포레이티드 | Ｈｉｖ 인테그라제 억제제 |
| JP2007528396A (ja) * | 2004-03-09 | 2007-10-11 | メルク エンド カムパニー インコーポレーテッド | Ｈｉｖインテグラーゼ阻害薬 |
| AU2005227258A1 (en) * | 2004-03-09 | 2005-10-06 | Merck & Co., Inc. | HIV integrase inhibitors |
| US7273859B2 (en) | 2004-05-12 | 2007-09-25 | Bristol-Myers Squibb Company | HIV integrase inhibitors: cyclic pyrimidinone compounds |
| US7115601B2 (en) | 2004-05-18 | 2006-10-03 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US7157447B2 (en) | 2004-05-28 | 2007-01-02 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| US7176196B2 (en) | 2004-05-28 | 2007-02-13 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| US7192948B2 (en) | 2004-05-28 | 2007-03-20 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| US7173022B2 (en) | 2004-05-28 | 2007-02-06 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| US7981879B2 (en) | 2005-03-31 | 2011-07-19 | Instituto di Ricerchi di Biologia Molecolare P. Angeletti S.p.A. | HIV integrase inhibitors |
| US7494984B2 (en) | 2005-08-31 | 2009-02-24 | Bristol-Myers Squibb Company | Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors |
| WO2007059125A2 (en) | 2005-11-15 | 2007-05-24 | Bristol-Myers Squibb Company | Hiv integrase inhibitors |
| US7902182B2 (en) | 2005-11-16 | 2011-03-08 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US8039458B2 (en) | 2005-11-17 | 2011-10-18 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| WO2007143446A1 (en) | 2006-05-30 | 2007-12-13 | Bristol-Myers Squibb Company | Spiro-condensed heterotricyclic compounds as hiv integrase inhibitors |
| US7893055B2 (en) | 2006-06-28 | 2011-02-22 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| CN102574854B (zh) | 2009-10-13 | 2014-04-16 | 伊兰科动物健康爱尔兰有限公司 | 大环整合酶抑制剂 |
| SG183484A1 (en) | 2010-02-26 | 2012-09-27 | Japan Tobacco Inc | 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv integrase inhibitor |
| EP2552923B1 (en) | 2010-04-02 | 2014-03-26 | Janssen R&D Ireland | Macrocyclic integrase inhibitors |
-
2014
- 2014-04-18 RS RS20180010A patent/RS56701B1/sr unknown
- 2014-04-18 EP EP17201148.8A patent/EP3330272B1/en active Active
- 2014-04-18 AU AU2014267951A patent/AU2014267951A1/en not_active Abandoned
- 2014-04-18 ME MEP-2018-4A patent/ME02977B/me unknown
- 2014-04-18 DK DK14798188.0T patent/DK2997033T3/da active
- 2014-04-18 PL PL14798188T patent/PL2997033T3/pl unknown
- 2014-04-18 LT LTEP14798188.0T patent/LT2997033T/lt unknown
- 2014-04-18 SI SI201430563T patent/SI2997033T1/en unknown
- 2014-04-18 HU HUE14798188A patent/HUE036384T2/hu unknown
- 2014-04-18 EP EP14798188.0A patent/EP2997033B1/en active Active
- 2014-04-18 ES ES14798188.0T patent/ES2656696T3/es active Active
- 2014-04-18 US US14/892,754 patent/US9643982B2/en active Active
- 2014-04-18 PT PT147981880T patent/PT2997033T/pt unknown
- 2014-04-18 WO PCT/CN2014/075685 patent/WO2014183532A1/en active Application Filing
- 2014-05-15 TW TW103117219A patent/TWI656122B/zh not_active IP Right Cessation
- 2014-05-16 AR ARP140101973A patent/AR096332A1/es not_active Application Discontinuation
-
2015
- 2015-01-28 NO NO15704618A patent/NO3058793T3/no unknown
-
2018
- 2018-01-16 HR HRP20180081TT patent/HRP20180081T1/hr unknown
- 2018-01-24 CY CY20181100097T patent/CY1119842T1/el unknown
- 2018-06-26 HK HK18108172.3A patent/HK1248685A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUE036384T2 (hu) | 2018-07-30 |
| ME02977B (me) | 2018-10-20 |
| TWI656122B (zh) | 2019-04-11 |
| HRP20180081T1 (hr) | 2018-02-23 |
| EP3330272A1 (en) | 2018-06-06 |
| NO3058793T3 (es) | 2018-03-17 |
| PL2997033T3 (pl) | 2018-04-30 |
| EP2997033A1 (en) | 2016-03-23 |
| EP2997033B1 (en) | 2017-11-15 |
| TW201524978A (zh) | 2015-07-01 |
| DK2997033T3 (da) | 2018-01-29 |
| EP3330272B1 (en) | 2021-02-17 |
| US9643982B2 (en) | 2017-05-09 |
| HK1248685A1 (zh) | 2018-10-19 |
| RS56701B1 (sr) | 2018-03-30 |
| US20160108059A1 (en) | 2016-04-21 |
| CY1119842T1 (el) | 2018-06-27 |
| AU2014267951A1 (en) | 2015-11-19 |
| ES2656696T3 (es) | 2018-02-28 |
| LT2997033T (lt) | 2018-02-12 |
| PT2997033T (pt) | 2018-01-25 |
| WO2014183532A1 (en) | 2014-11-20 |
| EP2997033A4 (en) | 2016-10-26 |
| SI2997033T1 (en) | 2018-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR096332A1 (es) | Compuestos heterocíclicos tricíclicos condensados como inhibidores de la integrasa del vih | |
| AR119651A1 (es) | Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington | |
| AR089865A1 (es) | Derivados de bencimidazol e imidazopiridinas como moduladores de canales de sodio | |
| AR110298A1 (es) | Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih | |
| AR123048A2 (es) | Moduladores de p2x7 | |
| ECSP16016726A (es) | Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del vih | |
| AR106472A1 (es) | Inhibidores de acc y usos de los mismos | |
| AR107170A1 (es) | Compuestos heterocíclicos tricíclicos condesados como inhibidores de integrasa del vih | |
| AR091981A1 (es) | Dihidropiridona p1 como inhibidores del factor xia | |
| AR117139A1 (es) | Derivados de piridooxazinona como inhibidores de monoacilglicerol ligasa (magl) | |
| AR108812A1 (es) | Proceso para preparar un derivado de piridona policíclica sustituida y cristal del mismo | |
| AR094496A1 (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
| AR117616A1 (es) | Compuestos anti-vih | |
| AR103252A1 (es) | Compuestos de quinazolina | |
| AR095198A1 (es) | Derivados de triazolona de piridinilo y piridinilo fusionado | |
| AR095192A1 (es) | Quinolina y quinazolinamidas como modulares de canales de sodio | |
| AR111407A1 (es) | Compuestos inhibidores de ask1 y usos de los mismos | |
| AR087791A1 (es) | Derivados de benzofurano con sustitucion heterociclica y metodos para el uso de los mismos en el tratamiento de enfermedades virales | |
| AR092306A1 (es) | Antibacterianos de fenicol | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR103251A1 (es) | Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico | |
| AR100808A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR112216A1 (es) | Derivados de azaquinolina | |
| AR108046A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| AR094550A1 (es) | Inhibidores de btk |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |